Paul Fredrickson

Title: Paul Fredrickson: Innovator in Nicotine Treatment

Introduction

Paul Fredrickson is a notable inventor based in Jacksonville, FL (US). He has made significant contributions to the field of medical research, particularly in the treatment of nicotine effects. His innovative approach aims to alleviate the adverse impacts of nicotine exposure on mammals.

Latest Patents

Fredrickson holds a patent for a method of treating the effects of nicotine. This invention provides methods and materials for addressing the consequences of nicotine exposure. Specifically, it involves administering a neurotensin receptor (NTR) agonist to a mammal that has been exposed to nicotine. The NTR agonist is typically administered in an effective amount to diminish or abolish the effects that nicotine has on the treated mammal. The patent includes the use of neurotensin (NT) polypeptide analogs, such as NT69L, as potential NTR agonists. Additionally, the invention encompasses compositions that combine an NTR agonist with other agents to help overcome nicotine effects, including hyperactivity, hypothermia, respiratory distress, and hypertension.

Career Highlights

Fredrickson is affiliated with the Mayo Foundation for Medical Education and Research, where he continues to advance his research and innovations. His work is pivotal in developing new treatments that can significantly improve the quality of life for individuals affected by nicotine.

Collaborations

Some of his notable coworkers include Mona Boules and Elliott Richelson. Their collaborative efforts contribute to the ongoing research and development in the field of nicotine treatment.

Conclusion

Paul Fredrickson's innovative work in treating the effects of nicotine showcases his dedication to medical research and invention. His contributions are vital in the quest to mitigate the harmful impacts of nicotine on health.